Decreased incidence of viral infections in liver transplant recipients. Possible effects of FK506?
Cytomegalovirus (CMV) is a major infectious complication of organ transplantation and its incidence is influenced by the type and intensity of immunosuppressive therapy employed. Using a new immunosuppressive agent FK506, CMV infection was observed in 30% and CMV disease in 15% of the 26 liver transplant recipients. Delayed onset of CMV disease was noted; the mean time to the occurrence of CMV disease being 137 days posttransplantation. No graft loss or mortality could be attributed to CMV infection. Mucocutaneous herpes simplex virus (HSV) infections were encountered in 19% of the patients, while no disease could be attributed to varicella zoster virus or Epstein-Barr virus (EBV). The contribution of FK506 to a decrease in viral morbidity and associated mortality bears further investigation.
Singh
N
N
Department of Medicine, VA Medical Center, Pittsburgh, Pennsylvania 15240.
Mieles
L
L
Yu
V L
VL
Starzl
T E
TE
D003586:Cytomegalovirus Infections / Q000453:epidemiology* / Q000517:prevention & control; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000453:epidemiology; D006085:Graft Survival; D006561:Herpes Simplex / Q000453:epidemiology; D006562:Herpes Zoster / Q000453:epidemiology; D006566:Herpesviridae Infections / Q000453:epidemiology; D004854:Herpesvirus 4, Human; D006801:Humans; D007165:Immunosuppression Therapy; D015994:Incidence; D016031:Liver Transplantation; D008297:Male; D008875:Middle Aged; D016559:Tacrolimus / Q000627:therapeutic use*; D013997:Time Factors
D016559:Tacrolimus